Delving into the Latest Updates on CHI-921 with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

standardized cannabis extract in sunflower oil, CHI-921

Target-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Sleep Initiation and Maintenance Disorders

Originator Organization

Canopy Growth Corp.

Active Organization-

Inactive Organization

Canopy Growth Corp.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Insomnia is a disorder where people are having trouble sleeping and can include difficulty falling asleep, staying asleep and waking up too early, as well as having unrefreshing sleep. CHI-921 is a cannabis extract in sunflower oil produced as a treatment for insomnia. This trial is designed to evaluate the efficacy and safety of CHI-921 on people with insomnia.

Start Date21 Mar 2019

Sponsor / Collaborator

Canopy Growth Corp.

[+5]

NCT00238550 / CompletedPhase 2

Randomised Control Trial Studying the Addition of CBME to Conventional Treatment for the Relief of Painful Diabetic Neuropathy

The study is designed to investigate the benefit of adding CBME to the existing treatment regime in the management of painful neuropathy.
Hypothesis:
The addition of CBME to the existing treatment regime will result in a significant improvement in both primary and secondary outcome measures.
The side effect profile and tolerability of CBME will be minimal and comparable to placebo.

Start Date01 Oct 2003

Sponsor / Collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

[+1]

100 Clinical Results associated with CHI-921

Login to view more data

100 Translational Medicine associated with CHI-921

Login to view more data

100 Patents (Medical) associated with CHI-921

Login to view more data

100 Deals associated with CHI-921

Login to view more data